KZ
faq
Негізгі бет
Қазірдің өзінде танымал
Тікелей эфир
Ұнаған бейнелер
Қайтадан қараңыз
Жазылымдар
Кіру
Тіркелу
Ең жақсы KZfaq
Фильм және анимация
Автокөліктер мен көлік құралдары
Музыка
Үй жануарлары мен аңдар
Спорт
Ойындар
Комедия
Ойын-сауық
Тәжірибелік нұсқаулар және стиль
Ғылым және технология
Жазылу
Mtech Access
At Mtech Access--Powered by Petauri™, we partner with Pharma and Medtech leaders to drive optimal global commercialisation. Programmes of support include:
•\tEvidence, pricing and access strategy
•\tDevelopment of a robust evidence base
•\tNational, regional and local reimbursement, and formulary inclusion
•\tCommunication of value to clinical and financial decision-makers
Follow our channel for insights from our in-house market access and HEOR specialists, as well as our external network of healthcare professionals and other stakeholders. Our videos offer:
- Insights into the NHS and other global healthcare systems
- Discussion of the latest trends in market access
- Explanation and discussion of health economics and evidence generation techniques
- Demos of our innovative digital presentation aids and dashboards
2:11
How do price negotiations for pharmaceuticals work in Canada?
Ай бұрын
1:49
Why are CADTH conditionally approving therapies?
Ай бұрын
1:56
Patient access challenges for orphan medicines in the Nordic region
Ай бұрын
2:08
Patient access challenges for rare diseases in the MENA region
2 ай бұрын
3:35
What is a partitioned survival model?
2 ай бұрын
4:23
What is a Cox regression model?
2 ай бұрын
47:44
Market access and reimbursement in Canada - changes at CADTH
2 ай бұрын
5:47
What is a discrete event simulation in health economics?
2 ай бұрын
2:48
What is the vision for primary care provider collaboratives in the NHS?
3 ай бұрын
3:32
What is a Markov model? - Health economics model structures
3 ай бұрын
0:54
3 challenges your proposal must address for NHS decision-makers
3 ай бұрын
59:11
Rare Disease market access in the MENA and Nordic regions
3 ай бұрын
4:21
What is a decision tree and how is it used in health economics?
3 ай бұрын
1:40
Does your medical device or diagnostic empower patients?
3 ай бұрын
3:26
Optimising NHS funding decisions: focusing on outcomes and ROI
3 ай бұрын
1:13
Opportunities to support secondary care in the NHS
3 ай бұрын
4:44
Introducing Mtech Access - Leaders in Global Pharma and Medtech Commercialisation
4 ай бұрын
2:19
Health economic evaluation for HTA in different markets
4 ай бұрын
1:00:16
How does funding flow in NHSE Regions?
4 ай бұрын
1:02:07
NHS policy for 2024/25: strategy and engagement in a world of uncertainty
4 ай бұрын
1:47
Get payer input and feedback on your evidence strategy early
5 ай бұрын
1:00:29
De-mystifying health economic model classifications and structures
5 ай бұрын
2:04
Is it worth investing time to launch in NHS Wales?
5 ай бұрын
1:52
How does specialised commissioning work in Wales?
5 ай бұрын
4:06
6 key early decisions when launching new Pharma and Medtech products
5 ай бұрын
1:41
What would the NHS in Wales want to see from an industry partner?
5 ай бұрын
53:25
Evidence strategy for Medical Technologies and Diagnostics
5 ай бұрын
2:09
What is changing for Pharma and Medtech industries in the US?
5 ай бұрын
3:13
How should Pharma respond to the changes to NHS specialised services?
5 ай бұрын
Пікірлер